Medtronic's CoreValve transcatheter aortic valve implant delivered "substantial" benefits in a study of extreme-risk patients, but a significant minority died or had "very poor" quality of life after TAVI, according to a study in Journal of the American College of Cardiology.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1F2sQFb
Cap comentari:
Publica un comentari a l'entrada